IL15 and colorectal neoplasm: An ongoing multicenter phase IIb clinical trial (NCT05419011) aims to evaluate whether the combination of trivalent adenovirus-5 (Tri-Ad5) vaccines and the IL-15 superagonist nogapendekin alfa inbakicept (N-803) can reduce the incidence of colorectal neoplasms in patients with LS.